AKBA 8-K 2026-11-05
Akebia Therapeutics, Inc. (AKBA) 8-K dated 2026-11-05 — accession 0001517022-26-000083.
Akebia Therapeutics, Inc. (AKBA) is a drug manufacturers - specialty & generic company listed on US.
AKBA revenue $36.9M
This 8-K covers: Results of operations (Item 2.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported AKBA revenue for 2025-12-31 was $236.2M. Net income was -$5.3M. Revenue was up 47.5% from 2024-12-31 to 2025-12-31. AKBA currently screens at market cap $260.1M.
Not investment advice. The AKBA SEC hub lists recent forms. The stock page is the research view.
- Revenue
- $36.9M
- Guidance
- expects to report initial data from this trial in 2027.
Why it matters
- expects to report initial data from this trial in 2027.
- Our strategic commercial priority remains making Vafseo standard of care for the treatment of anemia for patients on dialysis, and we are focused on continui…